参考文献/References:
[1] 杨培增.葡萄膜炎的研究进展[J].中华眼科杂志,2005,41(12):1149-1152.
YANG P Z.Research progress of uveitis[J].Chin J Ophthalmol,2005,41(12):1149-1152.
[2] AIRODY A,HEATH G,LIGHTMAN S,GALE R.Non-infectious uveitis:optimising the therapeutic response[J].Drugs,2016,76(1):27-39.
[3] ZHAO C,ZHANG M.Immunosuppressive treatment of non-infectious uveitis:history and current choices[J].Chin Med Sci J,2017,32 (1):48-61.
[4] GMEZ-GMEZ A,LOZA E,ROSARIO M P,ESPINOSA G,MORALES J M G R,HERRERAS J M,et al.Efficacy and safety of immunomodulatory drugs in patients with anterior uveitis:A systematic literature review[J].Medicine (Baltimore),2017,96(42):e8045.
[5] 黄世杰.FDA批准阿达木单抗治疗眼葡萄膜炎[J].国际药学研究杂志,2016,43(5):997.
HUANG S J.FDA approves Adalimumab for the treatment of uveitis[J].Int J Pharm Res,2016,43(5):997.
[6] HALE S,LIGHTMAN S.Anti-TNF therapies in the management of acute and chronic uveitis[J].Cytokine,2006,33:231-237.
[7] DICK A D,FORRESTER J V,LIVERSIDGE J,COPE A P.The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU)[J].Prog Retin Eye Res,2004,23:617-637.
[8] CERNOW S J,FALCIANI F,DURRANI O M,CHEUNG C M,ROSS E J,WLOKA K,et al.Multiplex bead immunoassay analysis of aqueous humor reveals distinct cytokine profiles in uveitis[J].Invest Ophthalmol Vis Sci,2005,46(11):4251-4259.
[9] TRACEY D,KLARESKOG L,SASSO E H,SALFEID J G,TAK P P.Tumor necrosis factor antagonist mechanisms of action:a comprehensive review[J].Pharmacol Ther,2008,117(2):244-279.
[10] FELDMANN M.Development of anti-TNF therapy for rheumatoid arthritis[J].Nat Rev Immunol,2002,2(5):364-371.
[11] MO J S,MATSUKAWA A,OHKAWARA S,YOSHINAGA M.Involvement of TNF alpha,IL-1 beta and IL-1 receptor antagonist in LPS-induced rabbit uveitis[J].Exp Eye Res,1998,66(5):547-557.
[12] COUTO C,SCHLAEN A,FRICK M,KHOURY M,LOPEZ M,HURTADO E,et al.Adalimumab treatment in patients with Vogt-Koyanagi-Harada disease[J].Ocul Immunol Inflamm,2018,26(3):485-489.
[13] SCHUSTER L,SAUTER M,UHI P,MEID A,HAEFELI W E,WEISS J,et al.Reporter cell assay-based functional quantification of TNF-α- antagonists in serum-a proof-of-principle study for adalimumab[J].Anal Biochem,2020,26(2):113646.
[14] GREBE K M,SALFELD J,KAYMAKCALAN Z.Lack of adalimumab’s complement dependent cytotoxicity on human cells expressing complement regulatory proteins[J].J Transl Med,2010,8(Suppl 1):9.
[15] FLORES-ROBLES B J,BLANCO-MADRIGAL J,SANABRIA-SANCHINEL A A,PASCUAL D H,DEMETROI-PABLO R,BLANCO R.Anti-TNFα therapy and switching in severe uveitis related to Vogt-Koyanagi-Harada syndrome[J].Eur J Rheumatol,2017,4(3):226-228.
[16] TAKAYAMA K,OBATA H,TAKEUCHI M.Efficacy of adalimumab for chronic Vogt-Koyanagi-Harada disease refractory to conventional corticosteroids and immunosuppressive therapy and complicated by central serous chorioretinopathy[J].Ocul Immunol Inflamm,2019,28(3):509-512.
[17] KWON H Y,WOO S J.A Case of recurrent vogt-koyanagi-harada disease successfully treated with adalimumab in young female adult patient[J].Korean J Ophthalmol,2020,34(1):92-93.
[18] BENY F,FARKAS A,HORVTH H,NAGY Z Z,SZEPESSY Z.Systemic biological treatment in ophthalmology[J].Orv Hetil,2019,160(44):1744-1750.
[19] STREET D,SIVAGURU A,SREEKANTAM S,MOLLAN S P.Vogt-Koyanagi-Harada disease[J].Pract Neurol,2019,19(4):364-367.
[20] SU E,OZA V S,LATKANY P.A case of recalcitrant pediatric Vogt-Koyanagi-Harada disease successfully controlled with adalimumab[J].J Formos Med Assoc,2019,118(5):945-950.
[21] JEROUDI A,ANGELES-HAN S T,YEH S.Efficacy of adalimumab for pediatric Vogt-Koyanagi-Harada syndrome[J].Ophthalmic Surg Lasers Imaging Retina,2014,45(4):332-334.
[22] ONO T,IWASAKI T,TERADA Y,ABE K,LEE J,MOCHIZUKI M,et al.Serum KL-6 elevation in a uveitis patient with Behet’s disease treated with adalimumab[J].Am J Ophthalmol Case Rep,2020,18:100660.
[23] SILVESTRI E,BITISSI A,BETTIOL A,EMMI G,URBAN M L,MATTIOLI I,et al.Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases:focus on Behet’s syndrome[J].Inflammopharmacology,2020,28(3):711-718.
[24] PIRANI V,PELLICCIONI P,DE TURRIS S,ROSATI A,FRANCESCHI A,PASANISI P,et al.Intraocular inflammation control and changes in retinal and choroidal architecture in refractory non-infectious uveitis patients after adalimumab therapy[J].Clin Med,2020,9(2):pii:E510.
[25] LAKRA R,SHAH A,KAUSHIK V,BISWAS J,DUTTA MAJUMDER P.Use of anti-tumour necrosis factor-alpha agents in the management of HLA-B-27-associated uveitis:The first case series from India[J].Ocul Immunol Inflamm,2020,14:1-5.
[26] HATEMI G,SEYAHI E,FRESKO I,TALARICO R,HAMURYUDAN V.One year in review 2019:Behet’s syndrome[J].Clin Exp Rheumatol,2019,121(6):3-17.
[27] CORDERO-COMA M,YILMAZ T,ONAL S.Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis[J].Ocul Immunol Inflamm,2013,21(1):19-27.
[28] JAFFE G J,DICK A D,BREZIN A P,NGUYEN Q D,THORNE J E,KESTELYN P,et al.Adalimumab in patients with active noninfectious uveitis[J].N Engl J Med,2016,375:932-943.
[29] NGUYEN Q D,MERRILL P T,JAFFE G J,DICK A D,KURUP S K,SHEPPARD J,et al.Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL Ⅱ):a multicentre,double-masked,randomised,placebo-controlled phase 3 trial[J].Lancet,2016,388:1183-1192.
[30] SUHLER E B,ADAN A,BREZIN A P,FORTIN E,GOTO H,JAFFE G J,et al.Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study:VISUAL Ⅲ[J].Ophthalmology,2018,125:1075-1087.
[31] TUGAL-TUTKUN I,ONAL S,ALTAN-YAYCIOGLU R,HUSEYIN ALTUNBAS H,URGANCIOGLU M.Uveitis in Behqet disease:an analysis of 880 patients[J].Am J Ophthalmol,2004,138(3):373-380.
[32] DEUTER C M,KTTER I,WALLACE G R,MURRAY P I,STBIGER N,ZIERHUT M.Behet’s disease:ocular effects and treatment[J].Prog Retin Eye Res,2008,27(1):111-136.
[33] MESQUIDA M,MOLINS B,LLORENQ V,HERNNDEZ M V,ESPINOSA G,DICK A D,et al.Current and future treatments for Behet’s uveitis:road to remission[J].Int Ophthalmol,2014,34(2):365-381.
[34] EL-ASRAR A M,STRUYF S,KANGAVE D,AL-OBEIDAN S S,OPDENAKKER G,GEBOES K,et al.Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis[J].Clin Immunol,2011,139:177-184.
[35] AHN J K,YU H G,CHUNG H,PARK Y G.Intraocular cytokine environment in active Behet’s uveitis[J].Am J Ophthalmol,2006,142:429-434.
[36] INTERLANDI E,LECCESE P,OLIVIERI I,LATANZA L.Adalimumab for treatment of severe Behet’s uveitis:a retrospective long-term follow-up study[J].Clin Exp Rheumatol,2014,32:S58-S62.
[37] FABIANI C,VITALE A,EMMI G,VANNOZZI L,LOPALCO G,GUERRIERO S,et al.Efficacy and safety of adalimumab in Behet’s disease-related uveitis:a multicenter retrospective observational study[J].Clin Rheumatol,2017,36:183-189.
[38] 杨培增.葡萄膜炎诊断与治疗[M].北京:人民卫生出版社,2009:754.
YANG PZ.Diagnosis and treatment of uveitis[M].Beijing:People’s Medical Publishing House,2009:754.
[39] BODAGHI B,TOUITOU V,FARDEAU C,CHAPELON C,LEHOANG P.Ocular sarcoidosis[J].Presse Med,2012,41(6 Pt 2):e349-354.
[40] ERCKENS R J,MOSTARD R L,WIJNEN P A,SCHOUTEN J S,DRENT M.Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis[J].Graefes Arch Clin Exp Ophthalmol,2012,250(5):713-720.
[41] YANG P,WAN W,DU L,ZHOU Q,QI J,LIANG L,et al.Clinical features of HLA-B27-positive acute anterior uveitis with or without ankylosing spondylitis in a Chinese cohort[J].Br J Ophthalmol,2018,102(2):215-219.
[42] BALEVIC S J,RABINOVICH C E.Profile of adalimumab and its potential in the treatment of uveitis[J].Drug Des Devel Ther,2016,10:2997-3003.
[43] SIMONINI G,TADDIO A,CATTALINI M,CAPUTO R,DE LIBERO C,NAVIGLIO S,et al.Prevention of flare recurrences in childhood-refractory chronic uveitis:an open-label comparative study of adalimumab versus infliximab[J].Arthritis Care Res (Hoboken),2011,63(4):612-618.
[44] HAMAM R N,BARIKIAN A W,ATONIOS R S,ABDULAAL M R,ALAMEDDINE R M,EL MOLLAYESS G,et al.Intravitreal adalimumab in active noninfectious uveitis:a pilot study[J].Ocul Immunol Inflamm,2016,24(3):319-326.
[45] NESTOROV I.Clinical pharmacokinetics of TNF antagonists:how do they differ?[J].Semin Arthritis Rheum,2005,34(5 Suppl 1):12-18.
[46] TRACEY D,KLARESKOG L,SASSO E H,SALFEID J G,TAK P P.Tumor necrosis factor antagonist mechanisms of action:a comprehensive review[J].Pharmacol Ther,2008,117(2):244-279.
[47] ZANNIN M E,BIEOLO C,GERLONI V M,MISEROCCHI E,PONTIKAKI I,PAROLI M P,et al.Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis:1-year follow up data from the Italian Registry[J].J Rheumatol,2013,40(1):74-79.
[48] SCHIMELING H,MINDEN K,FOEIDVARI I,GANSER G,HOSPACH T,HORNEFF G.Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis:the German Biologics JIA Registry[J].Arthritis Rheumatol,2014,66(9):2580-2589.
[49] RAMANAN A V,DICK A D,JONES A P,FRISWELL M,BAGULEY E,MAY K,et al.Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis[J].N Engl J Med,2017,376(17):1637-1646.
[50] SEVE P,VARRON L,BROUSSOLLE C,DENIS P,KODJIKIAN L.Sarcoidrelated uveitis occurring during adalimumab therapy[J].Ocul Immunol Inflamm,2012,20(1):59-60.